Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Hemoglobin ; 30(1): 131-7, 2006.
Article in English | MEDLINE | ID: mdl-16540426

ABSTRACT

In this retrospective study, we report the results of the association of a combined phlebotomy program and chelation in hereditary sideroblastic anemia (HSA) to reduce iron overload after bone marrow transplantation (BMT). A male HSA patient, not responding to pyridoxine treatment, was submitted to successful allogeneic BMT. As there was a persistence of a tissue iron overload, a regular phlebotomy program was started followed by chelation. A significant decrease of iron burden was obtained using a combined treatment with deferoxamine (DFO) and deferiprone (L1) in addition to the phlebotomy program. A 10-year follow-up shows a marked decrease in the concentration of serum ferritin, non-transferrin-bound iron (NTBI), liver iron and normal hemoglobin (Hb), which allows the patient to reach and maintain a good quality of life.


Subject(s)
Anemia, Sideroblastic/therapy , Bone Marrow Transplantation , Iron Chelating Agents/therapeutic use , Iron Overload/therapy , Liver Cirrhosis/therapy , Phlebotomy , Adolescent , Anemia, Sideroblastic/complications , Anemia, Sideroblastic/diagnosis , Biomarkers/blood , Chelation Therapy , Combined Modality Therapy , Deferiprone , Deferoxamine/therapeutic use , Follow-Up Studies , Humans , Iron Overload/complications , Liver Cirrhosis/complications , Male , Pyridones/therapeutic use , Retrospective Studies
3.
Eur J Haematol ; 74(6): 523-5, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15876257

ABSTRACT

We studied a patient with mild beta-thalassaemia major under treatment with the oral chelator deferiprone (DFP or L1) for about 10 yr (L1 veteran). Due to poor compliance with desferrioxamine, the patient started compassionate use of DFP at an age of 23 yr with a serum ferritin of 5200 microg/L. Monitoring iron overload by SQUID biosusceptometry revealed a dramatic decrease of liver iron concentrations from 4500 to 950 microg/g(liver) within 9.5 yr. A good clinical response to chelation treatment with DFP was observed together with an improvement of liver and cardiac function and a reduction in the hepatitis virus load.


Subject(s)
Iron Chelating Agents/administration & dosage , Pyridones/administration & dosage , beta-Thalassemia/drug therapy , Administration, Oral , Adult , Deferiprone , Female , Humans , Iron/metabolism , Liver/metabolism , beta-Thalassemia/metabolism
4.
Glycoconj J ; 20(2): 133-41, 2004.
Article in English | MEDLINE | ID: mdl-15001845

ABSTRACT

Acid glycosaminoglycans (GAGs) antioxidant activity was assessed in a fibroblast culture system by evaluating reduction of oxidative system-induced damage. Three different methods to induce oxidative stress in human skin fibroblast cultures were used. In the first protocol cells were treated with CuSO4 plus ascorbate. In the second experiment fibroblasts were exposed to FeSO4 plus ascorbate. In the third system H2O2 was utilised. The exposition of fibroblasts to each one of the three oxidant systems caused inhibition of cell growth and cell death, increase of lipid peroxidation evaluated by the analysis of malondialdehyde (MDA), decrease of reduced glutathione (GSH) and superoxide dismutase (SOD) levels, and rise of lactate dehydrogenase activity (LDH). The treatment with commercial GAGs at different doses showed beneficial effects in all oxidative models. Hyaluronic acid (HA) and chondroitin-4-sulphate (C4S) exhibited the highest protection. However, the cells exposed to CuSO4 plus ascorbate and FeSO4 plus ascorbate were better protected by GAGs compared to those exposed to H2O2. These outcomes confirm the antioxidant properties of GAGs and further support the hypothesis that these molecules may function as metal chelators.


Subject(s)
Copper/metabolism , Glycosaminoglycans/metabolism , Hydrogen Peroxide/metabolism , Iron/metabolism , Oxidative Stress/physiology , Antioxidants/metabolism , Cell Survival/physiology , Fibroblasts/metabolism , Humans , L-Lactate Dehydrogenase/metabolism , Lipid Peroxidation/physiology
5.
Life Sci ; 74(10): 1289-305, 2004 Jan 23.
Article in English | MEDLINE | ID: mdl-14697411

ABSTRACT

Oxidative stress is involved in the pathogenesis of chemically mediated liver injury. Since glycosaminoglycans possess antioxidant activity, the aim of this work was to assess the protective effects of hyaluronic acid and chondroitin-4-sulphate treatment in a model of carbon tetrachloride-induced liver injury. Liver damage was induced in male rats by an intraperitoneal injection of carbon tetrachloride (1 ml/kg in vegetal oil). Serum alanine aminotransferase and aspartate aminotransferase, hepatic malondialdehyde, plasma TNF-alpha, hepatic reduced glutathione and catalase, and myeloperoxidase, an index of polymorphonuclear infiltration in the jeopardised hepatic tissue, were evaluated 24 h after carbon tetrachloride administration. Carbon tetrachloride produced a marked increase in serum alanine aminotransferase and aspartate aminotransferase activities, primed lipid peroxidation, enhanced plasma TNF-alpha levels, induced a severe depletion of reduced glutathione and catalase, and promoted neutrophil accumulation. Intraperitoneal treatment of rats with hyaluronic acid (25 mg/kg) or chondroitin-4-sulphate (25 mg/kg) failed to exert any effect in the considered parameter, while the combination treatment with both glycosaminoglycans (12,5 + 12,5 mg/kg) decreased the serum levels of alanine aminotransferase and aspartate aminotransferase, inhibited lipid peroxidation by reducing hepatic malondialdehyde, reduced plasma TNF-alpha, restored the endogenous antioxidants, and finally decreased myeloperoxidase activity. These results suggest that hyaluronic acid and chondroitin-4-sulphate possess a different antioxidant mechanism and consequently the combined administration of both glycosaminoglycans exerts a synergistic effect with respect to the single treatment.


Subject(s)
Carbon Tetrachloride Poisoning/drug therapy , Carbon Tetrachloride Poisoning/pathology , Chemical and Drug Induced Liver Injury/drug therapy , Chemical and Drug Induced Liver Injury/pathology , Chondroitin Sulfates/pharmacology , Hyaluronic Acid/pharmacology , Liver/pathology , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Catalase/metabolism , Glutathione/metabolism , Glycosaminoglycans/metabolism , Lipid Peroxidation/drug effects , Male , Malondialdehyde/metabolism , Neutrophil Infiltration/drug effects , Oxidation-Reduction , Peroxidase/metabolism , Protein Biosynthesis , Rats , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...